Approval · Notice of Compliance 1603 · 1999
ZYBAN: Notice of Compliance 1603
Issued August 27, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1603
- Date
- August 27, 1999
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Maintenance dosing: treatment with zyban for up to 1 year to prevent relapse
- Therapeutic class
- Smoking cessation aid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZYBAN | Not yet assigned | — |
Medicinal ingredients
- BUPROPION HYDROCHLORIDE 150 MG per TAB